Who cares about pharma ESG efforts? Patients and patient groups do — and they want more, survey finds

Even as en­vi­ron­men­tal, so­cial and gov­er­nance (ESG) ef­forts have fall­en out of fa­vor among some in­vestors and busi­ness lead­ers, the ma­jor­i­ty of pa­tients are still in­vest­ed in phar­ma ef­forts.

That’s es­pe­cial­ly true when it comes to the “S” or so­ci­etal ef­fect phar­ma com­pa­nies can have, ac­cord­ing to Pa­tientView’s lat­est ESG sur­vey pub­lished to­day.

Among the more than 830 glob­al pa­tient groups sur­veyed, 85% said phar­ma com­pa­nies’ im­pact on so­ci­ety is “im­por­tant” or “very im­por­tant” to the peo­ple and pa­tients they rep­re­sent. An­oth­er 78% said cor­po­rate gov­er­nance, and 64% said en­vi­ron­men­tal ef­fects were “im­por­tant” or “very im­por­tant” to pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.